Metformina Eg Stada Group (Metformin Hydrochloride)

Metformin lowers blood sugar primarily by suppressing hepatic glucose production, enhancing the sensitivity of muscle and fat cells to insulin, and modestly reducing intestinal glucose absorption. These actions lower fasting and post‑prandial glucose levels without directly stimulating insulin secretion.

The exact dose of Metformina Eg Stada Group is determined by the prescribing clinician based on the individual’s glycemic targets, renal function, and tolerability. Starting doses are typically low and may be titrated upward, but the specific regimen should follow the prescriber’s instructions.

Safety data for metformin in pregnancy are limited, and it is generally classified as a drug to be used only if the potential benefit outweighs the risk. Breastfeeding mothers should consult their healthcare provider, as metformin is excreted in milk in small amounts.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metformin belongs to the biguanide class and is often preferred as first‑line therapy because it does not cause weight gain and has a low risk of hypoglycemia when used alone. In contrast, sulfonylureas stimulate insulin release and may cause hypoglycemia and weight gain, while newer agents like GLP‑1 agonists offer additional cardiovascular benefits but are more expensive.

Store the product at ambient temperature, preferably below 25 °C, in the original container to protect it from moisture and light. Keep the tablets out of reach of children and do not use if the packaging is damaged or the product appears discolored.

Metformina Eg Stada Group is taken orally, usually with meals to reduce gastrointestinal upset. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious adverse effect is lactic acidosis, a rare but potentially fatal condition that requires immediate medical attention. Other serious concerns include severe hypoglycemia when combined with insulin or sulfonylureas, and rare cases of hepatic dysfunction or severe skin reactions.

Metformina Eg Stada Group is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, and known hypersensitivity to metformin. Caution is also advised for individuals with significant hepatic disease or a history of lactic acidosis.